Q32 Bio (QTTB) Launches $200M Public Offering to Fund Clinical Development

Why Q32 Bio Stock Skyrocketed Today

The biotech is advancing a potential treatment for a common autoimmune disease.

Q32 Bio (QTTB) Shares Soar 60% After Positive Alopecia Treatment Trial Results

Q32 Bio (QTTB) stock soared 60% after bempikibart achieved primary endpoint in Phase 2a alopecia trial, showing 35.3% SALT score reduction w

Q32 Bio stock soared after its alopecia drug cleared a key clinical bar

The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a registration-dire

The biotech bi-weekly: a disease modeling research grant and an accelerator program for data-driven health start-ups

In this edition of the biotech bi-weekly: a new companion module makes direct RNA sequencing protocols more convenient, antibiotic design an

Case Study: How a QbD Approach Assisted with the Commercialization of a Stem Cell Therapeutic Drug, Accelerating the Product to Market

Scribe notes down IPO ambition to fund lipid-lowering genetic meds through clinical trials

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through c